Pricing Log in Create free account
Saturday 17 October 2026 Export PHAT’s income statement to Excel — free account

Phathom Pharmaceuticals, Inc.

PHAT Healthcare Biotechnology

Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024. In the quarter to June 2026, revenue grew 88.0%, EPS grew 80.0%, free cash flow grew 96.9% and total debt fell 19.8%, each against the same quarter a year earlier.

6.92 0.58 −7.73%
Market cap
$606.8M
P/E
0.0×
Fwd P/E
−15.9×
Dividend yield
—
F-score
4/9
Altman Z
−7.89
Beneish M
−1.39
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 38.83%

Capital & Financial Ratios $m

Market Cap 606.76
Revenue 239.66
Net Income (99.07)
Free Cash Flow (36.91)
Net Debt (17.89)
Current Ratio 1.92 (at or above 1.5: strong)
Debt/Equity (0.48) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (15.90) (negative: loss-making)
P/S ratio 2.42
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 76.56% (at or above 15%: strong)
Next Y EPS Growth 209.80% (at or above 15%: strong)
Next Y revenue growth 80.57% (at or above 10%: strong)
Next 5Y EPS Growth 22.16% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 381 297 130 182
Receivables 2 39 78 97
Inventory 1 3 6 8
Other — — — —
397 360 229 296
2023 2024 2025 Q'26
Payables 13 11 5 5
ST’ Debt — — — —
Other 7 20 35 37
39 86 132 154

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 58 74 — — —
’25 29 40 50 58 175
’24 2 7 16 30 55
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (2) — — —
’25 (85) (63) (14) (5) (167)
’24 (69) (71) (64) (63) (267)
’23 (40) (22) (32) (44) (138)
’22 (45) (26) (35) (41) (147)
’21 (50) (28) (29) (41) (148)
’20 (11) (9) (21) (28) (70)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (2) — — —
’25 (85) (63) (14) (5) (167)
’24 (69) (71) (64) (63) (267)
’23 (40) (22) (33) (44) (139)
’22 (45) (26) (35) (41) (148)
’21 (50) (28) (29) (41) (149)
’20 (12) (9) (21) (28) (71)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.37) (0.21) — — —
’25 (1.31) (1.05) (0.41) (0.29) (3.03)
’24 (1.42) (1.56) (1.32) (1.05) (5.29)
’23 (0.89) (0.84) (0.76) (1.39) (3.93)
’22 (1.07) (1.33) (1.32) (1.33) (5.05)
’21 (0.96) (1.00) (0.98) (0.95) (3.89)
’20 (0.62) (0.64) (1.02) (1.58) (3.88)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 18.51 22.06 17.42 6.10 5.84 6.07 2.21

Analyst estimates 2026–2028

Powerpack
High — — — 47.84 64.54 50.78 20.30 17.02 19.71 18.31
People
People Employees — — 16 25 55 77 112 452 427 371
Revenue/emp, $m — — 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.47
Income, $m
Income, $m Revenue — — — — — — — 1 55 175
Gross margin, % — — — 0.00 0.00 0.00 0.00 75.51 85.57 87.09
EBT — — (1) (255) (129) (144) (198) (202) (334) (221)
EBT margin, % — — 0.00 0.00 0.00 0.00 0.00 (29,558.94) (605.09) (126.35)
Net income — 0 (1) (255) (129) (144) (198) (202) (334) (221)
Depreciation — — — 0 2 4 3 2 3 4
Per share, $
Per share, $ Revenue — — 0.00 0.00 0.00 0.00 0.00 0.01 0.87 2.40
Earnings — — (0.21) (22.45) (3.88) (3.89) (5.05) (3.93) (5.29) (3.03)
Cash flow — — (0.17) (3.21) (2.10) (4.01) (3.75) (2.68) (4.22) (2.29)
Capex — — 0.00 (2.22) (0.03) (0.01) (0.03) (0.03) 0.00 0.00
Free cash flow — — (0.17) (5.43) (2.13) (4.02) (3.77) (2.71) (4.22) (2.29)
Book value — — (0.21) 20.05 5.85 1.95 (1.91) (1.42) (4.01) (6.01)
Shares, m — — 6 11 33 37 39 51 63 73
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 0.00
P/S — — — — — — — 0.00 9.28 6.91
P/B — — — — — — — 0.00 0.00 0.00
EV/Sales — — — — — — — 0.00 7.74 7.42
EV/FCF — — — — — — — (1.70) (1.60) (7.78)
Cash, $m
Cash, $m Operating cash flow — — (1) (37) (70) (148) (147) (138) (267) (167)
Capex — — — (25) (1) 0 (1) (2) 0 0
Free cash flow — — (1) (62) (71) (149) (148) (139) (267) (167)
Balance, $m
Balance, $m Working capital — — (1) 252 236 168 134 359 274 97
Total debt — — 2 23 47 90 95 138 201 209
Net debt — — 1 (221) (241) (94) (60) (244) (96) 79
Shareholders’ equity — — (1) 228 194 72 (75) (73) (254) (438)
Returns, %
Returns, % ROA — — (285.59) (197.71) (46.74) (59.39) (111.63) (69.68) (84.41) (69.41)
ROIC — — 0.00 (931.32) 0.00 0.00 0.00 0.00 0.00 0.00
ROE — — (1.14) (225.11) (61.14) (108.01) 14,877.58 273.21 204.89 63.97
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Phathom Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
WVE WAVE Life Sciences Ltd. $628.6M — (loss-making) — (loss-making) −73.88% (below 0%: shrinking) n/m −17.59% (below 0%: shrinking) 100.00% (3,248.33%) Compare
CLYM Climb Bio, Inc. $626.6M — (loss-making) — — n/m +3.73% (above 0%: growing) — 0.00% Compare
NVCT Nuvectis Pharma, Inc. $618.0M — (loss-making) — — n/m −34.57% (below 0%: shrinking) — 0.00% Compare
SLDB Solid Biosciences Inc. $615.5M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −39.56% (below 0%: shrinking) 0.00% 0.00% Compare
ZVRA Zevra Therapeutics, Inc. $609.9M 10.5× 10.5× +53.25% (above 0%: growing) −88.71% (below 0%: shrinking) +670.87% (above 0%: growing) 96.16% 42.30% Compare
PHAT Phathom Pharmaceuticals, Inc. $606.8M — (loss-making) — (loss-making) +88.02% (above 0%: growing) n/m +96.86% (above 0%: growing) 79.68% (5.34%)
OLMA Olema Pharmaceuticals, Inc. $601.1M — (loss-making) — — n/m −54.33% (below 0%: shrinking) 0.00% 0.00% Compare
CRMD CorMedix Inc $581.5M 3.0× 16.5× +156.52% (above 0%: growing) +13.79% (above 0%: growing) +185.90% (above 0%: growing) 75.66% 42.10% Compare
SLN Silence Therapeutics PLC Sponsored ADR $581.1M — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00% Compare
Median of peers $612.7M — — +53.25% — −6.93% 85.91% 0.00%

All 614 Biotechnology stocks →

Phathom Pharmaceuticals, Inc. (PHAT) key facts

  • Strength: Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024.
  • Phathom Pharmaceuticals, Inc. (PHAT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PHAT traded at $6.92, a market capitalization of $606.8 million.
  • Return on equity was 64.0% and debt-to-equity -0.48.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −7.89 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Phathom Pharmaceuticals, Inc. (PHAT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PHAT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com